Huiyu Pharmaceutical (688553.SH) subsidiary, injectable teicoplanin, has obtained marketing authorization in Ireland.

Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Seacross Phar...

Zhitong FinanceJan 16 17:50

Sichuan Huiyu Pharmaceutical Gains French, Egyptian Approval for Two Injections

MT NewswiresJan 13 17:45

Express News | Huiyu Pharmaceutical: Injectable Teicoplanin and Docetaxel injection have respectively obtained marketing approval in France and Egypt.

BreakingsJan 10 16:42

Lakeside Partners With Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

PR NewswireJan 7 21:30

Huiyu Pharmaceutical (688553.SH): Re-certified as a high-tech enterprise.

On December 31, Gelonghui reported that Huayu Pharmaceutical (688553.SH) announced that according to the announcement released on December 30, 2024, by the Office of the National High-tech Enterprises Recognition Management Work Leading Group, the company has been included in the third batch of high-tech enterprises recognized and filed by the Sichuan Province Recognition Institutions in 2024. The company has once again passed the recognition of high-tech enterprises, with certificate number: GR202451002753, valid for three years. The company previously passed the recognition of high-tech enterprises in 2021.

Gelonghui FinanceDec 31, 2024 18:06

Express News | Huiyu Pharmaceutical: Director and senior management personnel Ding Zhao received the administrative penalty decision from the SiChuan Regulatory Bureau.

BreakingsDec 31, 2024 18:06